Ion channel modulating compounds and uses thereof

• US 7,057,053 B2
• Filed: 12/21/2004
• Issued: 06/06/2006
• Est. Priority Date: 10/06/2000
• Status: Expired due to Term

• Current Assignee: Correvio International SARL (ADVANZ PHARMA Corp. Ltd.)
• Original Assignee: Cardiome Pharma Corp. (ADVANZ PHARMA Corp. Ltd.)
• Inventors: Plouvier, Bertrand M. C., Zolotoy, Alexander B., Sheng, Tao, Wall, Richard A., Zhu, Jeff Jiqun, Yong, Sandro L., Walker, Michael J. A., Beatch, Gregory N.
• Primary Examiner(s): Saeed, Kamal A.
• Assistant Examiner(s): ANDERSON, REBECCA L
• Application Number:
  US11/018,428
• Publication Number:
  US 20050209307A1
• Time in Patent Office: 532 Days
• Field of Search: 548/541, 514/424
• US Class Current: 548/541
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: C07D 207/12 Oxygen or sulfur atoms
• CPC Class Codes: C07D 209/36 in position 3, e.g. adrenochrome

Abstract

Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.

Claims

1. A compound having the following structure:

2. The compound of claim 1 wherein the compound is a mixture of isomers.

3. The compound of claim 2 wherein the compound has the following structure:

4. The compound of claim 2 wherein the compound has the following structure:

5. The compound of claim 1 wherein the compound is an isolated isomer.

6. The compound of claim 5 wherein the compound has the following structure:

7. The compound of claim 5 wherein the compound has the following structure:

8. The compound of claim 5 wherein the compound has the following structure:

9. The compound of claim 5 wherein the compound has the following structure:

10. A composition comprising a compound of any one of claims 1–

9, in combination with a pharmaceutically acceptable carrier, excipient or diluent.